X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.
Lead Product(s): TOTUM•63
Therapeutic Area: Endocrinology Product Name: TOTUM•63
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
TOTUM•854, a patented active substance based on a combination of plant extracts, is developed to reduce blood pressure in people with mild to moderate hypertension, by reducing angiotensin I-converting enzyme (ACE1) activity.
Lead Product(s): TOTUM•854
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totum-854
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
TOTUM•070 is a combination of plant extracts, with no phytosterol or red yeast rice content. TOTUM•070 is being developed with a view to obtaining a proprietary health claim relating to the reduction of blood LDL cholesterol, a risk factor for cardiovascular diseases.
Lead Product(s): Totum•070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totum•070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: TP ICAP Midcap
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 09, 2022
Details:
TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes, has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study.
Lead Product(s): Totum-63
Therapeutic Area: Endocrinology Product Name: Totum-63
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: INAF
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
This innovative study is the first to characterize the metabolites of TOTUM•070 in humans and their mode of action in the liver in a population of 10 healthy volunteers. TOTUM•070 was tested at its clinical daily dose (5g), used also in the Phase II HEART clinical trial.
Lead Product(s): Totum•070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totum•070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
The results, obtained in vivo on models predictive of hypertension in humans, showed that TOTUM•854 is effective in preventing hypertension.
Lead Product(s): TOTUM•854
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM•854
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Avignon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Riom R&D platform.
Lead Product(s): TOTUM-854
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-854
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Avignon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol.
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
The clinical study HEART on TOTUM-070, a Phase II randomized placebo-controlled and double blind study, has just been initiated in accordance with the road map, the study protocol having been submitted to the French health authorities.
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
EASD has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.
Lead Product(s): Totum-63
Therapeutic Area: Endocrinology Product Name: Totum-63
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
